Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion
AXIM BIOTECHNOLOGIES, INC.
B-cell Acute Lymphoblastic Leukemia
1 trial -
Formosa 1-Breath Free (NRICM101)
Hospital Authority, Hong Kong
Influenza Viral Infections
1 trial -
Fortecortin® 2 mg Tabletten, Privigen 100 mg/ml solution for infusion, Privigen 100 mg/ml solution for infusion, KIOVIG 100 mg/ml solution for infusion, Imnovid 4 mg hard capsules, Privigen 100 mg/ml solution for infusion, Pomalidomide, KIOVIG 100 mg/ml solution for infusion, Imnovid 1 mg hard capsules, KIOVIG 100 mg/ml solution for infusion, Pomalidomide, Dexamethasone Tablets BP 2.0mg, JNJ-64407564, JNJ-64407564, Pomalidomide, DARZALEX 1800 mg solution for injection, Imnovid 3 mg hard capsules, Dexamethas
Janssen-Cilag International N.V.
Relapsed or Refractory Multiple Myeloma
1 trial -
Fortecortin® 2 mg Tabletten, teclistamab, Lenalidomide Mylan 25 mg hard capsules, JNJ-64407564, Dexamethasone Tablets BP 2.0mg, Lenalidomide Accord 10 mg hard capsules, JNJ-64407564, Lenalidomide Mylan 15 mg hard capsules, Lenalidomide Accord 5 mg hard capsules, Dexamethason 4 mg JENAPHARM®, Lenalidomide Mylan 5 mg hard capsules, Privigen 100 mg/ml solution for infusion, DARZALEX 1800 mg solution for injection, Lenalidomide Accord 15 mg hard capsules, Lenalidomide Accord 25 mg hard capsules, Privigen 100 mg
Janssen-Cilag International N.V.
Multiple Myeloma
1 trial -
Fosmanogepix, POSACONAZOLE , AMPHOTERICIN B , CASPOFUNGIN , ISAVUCONAZOLE , MICAFUNGIN , TERBINAFINE , VORICONAZOLE , ANIDULAFUNGIN , -, Fosmanogepix
Lacuna Pharma Pty Ltd
Invasive mold infections caused by Aspergillus spp., Fusarium spp., Lomentospora prolificans, Mucorales fungi, or other multidrug resistant molds
1 trial -
Fractional CO2 Laser
Hospital Authority, Hong Kong
Treatments of Striae Gravidarum
1 trial -
Fremanezumab, AJOVY 225 mg solution for injection in pre-filled pen
Lacuna Pharma Pty Ltd
Episodic and Chronic Migraine
1 trial -
G-Pen (glucagon injection)
Xeris Biopharma Holdings
Hypoglycemia
1 trial -
GC1107
Green Valley (Shanghai) Pharmaceuticals Co.,
Bacterial Infections
1 trial -
GENTAMICIN , CEFAZOLIN , VANCOMYCIN , TEDIZOLID , PRISTINAMYCIN , SULFAMETHOXAZOLE AND TRIMETHOPRIM , CEFOTAXIME, CEFTAROLINE FOSAMIL , AMOXICILLIN , OFLOXACIN , CLINDAMYCIN , TIGECYCLINE , LINEZOLID , AMIKACIN , LYMECYCLINE , CEFTRIAXONE , TEICOPLANIN , DOXYCYCLINE , PIPERACILLIN AND BETA-LACTAMASE INHIBITOR , Xydalba 500 mg powder for concentrate for solution for infusion, LEVOFLOXACIN , DELAFLOXACIN , CIPROFLOXACIN , CLOXACILLIN , OXACILLIN , DAPTOMYCIN , AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , RIFAMP
Pari Pharma GmbH
Catheter related bloodstream infections due to Staphylococcus aureus
1 trial -
GS-1720, Biktarvy 50 mg/200 mg/25 mg film-coated tablets, GS-4182
Gilead Sciences Pty Limited
HIV-1 Infection
1 trial -
GS-4182, Biktarvy 50 mg/200 mg/25 mg film-coated tablets, GS-1720
Gilead Sciences Pty Limited
HIV-1 Infection
1 trial -
GS1191-0445 injection
Gritgen Therapeutics Co.,
Hemophilia A
1 trial -
GTX/UX Diluent and Flush Solution, GTX-102, ELLIOTTS B SOLUTION (buffered intrathecal electrolyte/dextrose injection)
Lacuna Pharma Pty Ltd
Angelman Syndrome
1 trial -
Gardasil 9 suspension for injection in a pre-filled syringe. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed)
Merck Sharp and Dohme
9vHPV vaccine is indicated in females ≥ 9 years of age in the prevention of cervical, vulvar, vaginal, and anal cancer; precancerous or dysplastic lesions; and persistent infections caused by Human Papillomavirus (HPV) types 16, 18, 31, 33, 45, 52, and 58, and genital warts (condyloma acuminata) caused by HPV types 6 and 11.
1 trial -
Gardasil 9 suspension for injection in a pre-filled syringe. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed), Gardasil 9 suspension for injection. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed), Gardasil 9 suspension for injection in a pre-filled syringe. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed), Placebo formulation of Gardasil, Gardasil 9 suspension for injection in a pre-filled syringe. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed)
The George Institute
Patients with primary HPV high-grade squamous intra-epithelial lesions (HSIL) at any site (vulvar VIN, vaginal VaIN, penile (PeIN), cervical CIN, anal AIN) at the time of treatment.
1 trial -
Gardasil 9 suspension for injection in a pre-filled syringe. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed), Gardasil, suspension for injection in a pre-filled syringe Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed), SODIUM CHLORIDE
Pari Pharma GmbH
External Genital Warts (EGW)
1 trial -
Generic Ivermectin Lotion 0.5%
Teva Pharma GmbH
Head Lice
1 trial -
Gepotidacin
GlaxoSmithKline
Urinary Tract Infections
1 trial -
Ginkgo Diterpene Lactone Meglumine Injection
Universal Integrated
Ischemic Stroke
1 trial -
Ginkgo diterpene lactone meglumine injection
Universal Integrated
Ischemic Stroke, Acute
1 trial -
Glycopyrronium bromide
Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
1 trial -
Grafalon 20 mg/ml concentrato per soluzione per infusione
The George Institute
To analyze whether the anti-rejection treatment of borderline lesions can modify the expression and klotho levels, as well as proinflammatory cytokines that regulate klotho expression at both years post-transplant., Know in a controlled and randomized clinical trial, carried out in low-risk patients immunological and stable renal function, if the treatment of BL lesions, detected in the third month post-transplant, with rabbit polyclonal antilymphocytic globulin prevents or slows the progression of chronic histological lesions of the graft (FIAT) and the deterioration of its function compared to clinical follow-up conventional, after two years of post-transplant follow-up.
1 trial -
Gum chewing
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co.,
Recovery of Bowel Function, Due to Gum Chewing
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources